These investments will create an additional 30 new jobs. Part of the latest gene therapy generation against leukaemia will be produced in Austria in the future. The CAR-NK cell therapy is the latest and next generation to be made available to patients as an additional therapy alternative when other forms of treatment reach their limits. The abbreviation CAR stands for "chimeric antigen receptor" and NK means "natural killer cells". This project is currently in its development phase and is being investigated by Takeda to treat Non-Hodgkin lymphoma and chronic lymphocytic leukaemia.
In order to successfully operate this new type of gene therapy, a so-called vector as a vehicle is required. The vector can transport genetic elements in the body cells. This "gene taxi" will be produced in Orth an der Donau in the future. The vector will subsequently be further processed at other Takeka sites into an innovative new type of CAR-NK cell therapy to help fight against leukaemia in the patient's own body.
Takeda is a global biopharmaceutical company based in Japan which has specialised in treating people with rare and complex diseases, amongst other priorities.
Takeda is Austria's largest pharmaceutical employer, with a staff of about 4,500 people at its production sites in Vienna, Linz and Orth an der Donau.
Continue reading and learn how ABA - Invest in Austria can assist your company to grow in Austria.